Acadia Pharmaceuticals, a leader in neuroscience and rare disease, is working to advance next-generation therapies. The company's commercial portfolio already includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. Acadia is also developing the next wave of therapeutic advancements with a pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs.

Catherine Owen Adams, the CEO of Acadia, discusses her firm's commitment to turning scientific promise into meaningful innovation that can help make a difference for underserved neurological and rare disease communities around the world. Catherine speaks with Tim Stenovec and Emily Graffeo on Bloomberg Businessweek Daily.